BACKGROUND: The influence of primary systemic therapy (PST) on the expression of relevant therapeutic markers is still under investigation. PATIENTS AND METHODS: Corresponding "baseline" biopsies and post-chemotherapy surgical specimens from 87 patients treated with neoadjuvant anthracycline- or taxane-based chemotherapy were analysed for the expression of the oestrogen receptor (ER), the progesterone receptor (PR), the B-cell lymphoma protein 2 (Bcl-2), the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (Her2/neu), the tumour protein p53 and the proliferation-related Ki-67 antigen. RESULTS: The pathological response rate was 70%. Twenty-three tumours (26%) changed hormone receptor classification after chemotherapy (7, ER; 16 PR). A significant change was also observed for Her2/neu status. Eleven tumours which were positive prior to PST down-regulated Her2/neu after chemotherapy. The median Ki-67 index decreased from 30% before to 13% after treatment (p<0.01). Minor changes were observed in the expression of Bcl-2 and p53 (9%). Only the reduction of Ki-67 was associated with pathological response to PST. CONCLUSION: Her2/neu status as well as ER and PR status should be re-evaluated on post-chemotherapy surgical specimens since changes can be observed.
BACKGROUND: The influence of primary systemic therapy (PST) on the expression of relevant therapeutic markers is still under investigation. PATIENTS AND METHODS: Corresponding "baseline" biopsies and post-chemotherapy surgical specimens from 87 patients treated with neoadjuvant anthracycline- or taxane-based chemotherapy were analysed for the expression of the oestrogen receptor (ER), the progesterone receptor (PR), the B-cell lymphoma protein 2 (Bcl-2), the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (Her2/neu), the tumour protein p53 and the proliferation-related Ki-67 antigen. RESULTS: The pathological response rate was 70%. Twenty-three tumours (26%) changed hormone receptor classification after chemotherapy (7, ER; 16 PR). A significant change was also observed for Her2/neu status. Eleven tumours which were positive prior to PST down-regulated Her2/neu after chemotherapy. The median Ki-67 index decreased from 30% before to 13% after treatment (p<0.01). Minor changes were observed in the expression of Bcl-2 and p53 (9%). Only the reduction of Ki-67 was associated with pathological response to PST. CONCLUSION:Her2/neu status as well as ER and PR status should be re-evaluated on post-chemotherapy surgical specimens since changes can be observed.
Authors: Siwei Wei; Lingyan Liu; Jian Zhang; Jeremiah Bowers; G A Nagana Gowda; Harald Seeger; Tanja Fehm; Hans J Neubauer; Ulrich Vogel; Susan E Clare; Daniel Raftery Journal: Mol Oncol Date: 2012-10-25 Impact factor: 6.603
Authors: Celina Ang; Eileen M O'Reilly; Richard D Carvajal; Marinela Capanu; Mithat Gonen; Laurence Doyle; Ronald Ghossein; Lawrence Schwartz; Gria Jacobs; Jennifer Ma; Gary K Schwartz; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2012-11
Authors: Xiaoxian Li; Michael T Deavers; Ming Guo; Ping Liu; Yun Gong; Constance T Albarracin; Lavinia P Middleton; Lei Huo Journal: Mod Pathol Date: 2012-08-17 Impact factor: 7.842
Authors: T Hirata; C Shimizu; K Yonemori; A Hirakawa; T Kouno; K Tamura; M Ando; N Katsumata; Y Fujiwara Journal: Br J Cancer Date: 2009-10-06 Impact factor: 7.640